Aclaris Therapeutics (ACRS) Other Accumulated Expenses (2014 - 2026)

Aclaris Therapeutics' Other Accumulated Expenses history runs 13 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 2.63% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 2.63% YoY), while the FY2025 annual figure was $504000.0, down 17.24% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $2.8 million, up from $504000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.8 million in Q1 2026, with the low at $217000.0 in Q4 2022.
• The 5-year median for Other Accumulated Expenses is $1.7 million (2022), against an average of $1.5 million.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses sank 87.49% in 2022, then surged 1111.06% in 2023.
• Aclaris Therapeutics' Other Accumulated Expenses stood at $217000.0 in 2022, then soared by 1111.06% to $2.6 million in 2023, then sank by 76.83% to $609000.0 in 2024, then retreated by 17.24% to $504000.0 in 2025, then jumped by 449.8% to $2.8 million in 2026.
• Business Quant data shows ACRS's Other Accumulated Expenses at $2.8 million in Q1 2026, $504000.0 in Q4 2025, and $387000.0 in Q3 2025.